is a biopharmaceutical research and development oncology company based in los angeles california the cytrx oncology pipeline includes clinical trials involving their lead drug aldoxorubicin aldoxorubicin formerly inno 206 is a modified form of doxorubicin the popular anthracycline chemotherapeutic agent known as red death anthracyclines are a class of drugs that are among the most commonly used agents in the treatment of cancer doxorubicin the first anthracycline to gain approval has demonstrated efficacy in a wide variety of cancers including breast cancer lung cancer sarcomas and lymphomas however doxorubicin is associated with side effects such as myelosuppression gastrointestinal disorders mucositis stomatitis cumulative cardiotoxicity and extravasation cytrx plans to expand its pipeline of oncology candidates at its laboratory facilities in freiburg germany based on novel linker technologies that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites the corporate website is http www cytrx com aldoxorubicin steven arthur kriegsman is the president and ceo aldoxorubicin formerly inno 206 is a tumor targeted doxorubicin conjugate specifically it is the 6 maleimidocaproyl hydrazone of doxorubicin essentially this chemical name describes doxorubicin doxo attached to an acid sensitive linker emch completed preclinical and clinical trials